Select Language

CD163

CD163 Overview

English Name	Scavenger receptor cysteine-rich type 1 protein M130	Approved Drugs	1
Drugs in Clinical Trials	1	Target Synonym	CD163，M130，Scavenger receptor cysteine-rich type 1 protein M130，sCD163，CD163 Molecule，Hemoglobin Scavenger Receptor，CD163 Antigen，Macrophage-Associated Antigen，SCARI1，MM130
Highest Development Stage	Approved

English Name	Scavenger receptor cysteine-rich type 1 protein M130
Target Synonym	CD163，M130，Scavenger receptor cysteine-rich type 1 protein M130，sCD163，CD163 Molecule，Hemoglobin Scavenger Receptor，CD163 Antigen，Macrophage-Associated Antigen，SCARI1，MM130
Approved Drugs	1
Drugs in Clinical Trials	1
Highest Development Stage	Approved

CD163 Product List

Product Category
Protein (1)
Product Status
Launched (1)
Species
Human (1)
Tag
His Tag (1)
Conjugate
Unconjugated (1)

Cat. No.	Species	Host	Product Description	Structure	Purity	Feature
CD3-H52E8	Human	HEK293	Human CD163 Protein, His Tag

Total: 1

CD163 Background

Scavenger receptor cysteine-rich type 1 protein M130 (CD163) is also known as hemoglobin scavenger receptor, which is a scavenger receptor for the hemoglobin-haptoglobin complex. CD163 has also been shown to mark cells of monocyte/macrophage lineage. A soluble form of the receptor exists in plasma, commonly denoted sCD163. sCD163 is generated by ectodomain shedding of the membrane bound receptor. sCD163 is upregulated in a large range of inflammatory diseases including liver cirrhosis, type 2 diabetes, macrophage activation syndrome, Gaucher's disease, sepsis, HIV infection, rheumatoid arthritis and Hodgkin Lymphoma.

CD163 Synonyms

CD163,M130

Clinical Drug Information

English Name	Research Code	Highest Development Stage	Company	Indication	Clinical Trial
OR-2805	OR-2805	Phase 2 Clinical	OncoResponse Inc	Carcinoma, Non-Small-Cell Lung; Leiomyosarcoma; Liposarcoma; Melanoma; Neoplasm Metastasis; Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck	Details

Marketed Drug Information

English Name	Research Code	Highest Development Stage	Company	Earliest Brand Name	Earliest Approval Country	Earliest Indication	Earliest Approval Company	Earliest Approval Date	Indication	Clinical Trial
Tetrachlorodecaoxide	OXO-K993; WF-10; TCDO	Approved	Nuvox Pharma LLC	Oxoferin, Immunokine, WF10	Thailand	Inflammation; Rhinitis, Allergic	null	1997-01-01	Diabetic Foot; HIV Infections; Inflammation; Rhinitis, Allergic	Details